Echo IQ (EIQ) Q4 2026 TU earnings summary

Executive summary

• Secured a binding Heads of Agreement with Pro Medicus for up to $20m investment and US commercial partnership, providing access to a leading medical imaging platform and extensive US network.

• Completed a ~$110m institutional placement to accelerate US expansion, product development, and cardiovascular AI platform growth.

• Expanded US commercial pipeline to over 70 hospitals, including three enterprise proposals covering 300+ hospitals.

• Launched EchoSolv VIEW and SHADOW deployment programs, driving increased adoption and providing new routes to market.

• Processed over 10,200 echocardiograms in the quarter, up 20% sequentially and over 400% year-over-year, indicating accelerating commercial adoption.

• Secured exclusive Advara HeartCare data licensing agreement for up to one million deidentified echocardiography studies, enhancing AI product development.

• Established research collaboration with Mayo Clinic to evaluate AI platform in cardio-oncology, supporting future product expansion.

• Strengthened executive leadership and clinical advisory network to support US commercial growth.

Financial highlights

• Cash and cash equivalents at 30 June 2026 were $8.7m, down from $11.14m at 31 March 2026, but improved post-period with the $110m placement and Pro Medicus agreement.

• Net cash used in operating activities for the quarter was $(2.73)m, with year-to-date operating cash outflows of $(10.57)m.

• Payments to related parties during the quarter totaled $156,000.

• Estimated quarters of funding available at quarter end was 3.2.

Outlook and guidance

• Near-term priorities include finalizing the Pro Medicus partnership, converting US pipeline into deployments, engaging with FDA for EchoSolv HF, and expanding reimbursement opportunities.

• Medium-term focus on expanding enterprise deployments, broadening the EchoSolv platform, leveraging proprietary datasets, and progressing additional strategic partnerships.